Tilray Brands, Inc. Q1FY27 Earnings Call - TILRAY BRANDS INC

Explicit Guidance:

• Reaffirmed Fiscal Year 2027 Adjusted EBITDA guidance of $68 million to $75 million.
• Guidance reflects expectations for the full fiscal year 2027, incorporating anticipated second-half seasonality and integration benefits.

Business-Segment Outlook:

• International Cannabis:
  • Portugal facility expected to deliver >40 metric tons of flower at full capacity in fiscal 2027.
  • Germany's Apria RX operating at 100% capacity; Portugal and Germany combined with Canadian low-cost production to form a top-tier global operating model.
  • Expansion into Australia and New Zealand to scale medical cannabis operations.
  • In the UK, objective to double the patient base for Life (medical cannabis subsidiary) and shorten the patient journey.
  • EU GMP shipments for medical flower and oil expected to accelerate with flower volumes up 110% and oil up 150% year-over-year in Q1, with continued growth anticipated.
• Beverage:
  • BrewDog to serve as a primary growth engine with a global footprint; brand sales in top six UK off-trade retailers up 187% following "Choose Craft" campaign launch.
  • BrewDog secured 9,000 new distribution points and launched eight new on-trade partnerships; remains self-financing and profitable since Q2.
  • Carlsberg Partnership: Beginning January 1, 2027, Tilray will produce, market, and sell Carlsberg, Carlsberg Elephant, and 1664 Blanc across all U.S. channels, expected to deliver immediate scale revenue and deepen distributor relationships.
  • U.S. Beer: Aiming to gain market share in key regions; now the #2 craft vendor in Georgia and the West, #4 in New York; Sweetwater is #3 craft brand in Georgia (12% share).
  • Portfolio optimization continuing with brand rationalization (e.g., selling Atwater) and brewery consolidation to 5–6 strategic facilities.
  • Long-term target to expand into seltzers, highball energy drinks, and water to complement core beer portfolio.
  • THC Beverages: Aiming to expand distribution in Canada through food establishments, restaurants, bars, and beer stores in Ontario and other provinces; potential to unlock a $100M+ excise tax revenue opportunity for governments.
• Wellness:
  • Manitoba Harvest expanding into adjacent grain-based and plant-based products to broaden health and wellness portfolio.
  • Focus on growth via grocery, natural, and e-commerce channels.
• Distribution:
  • CC Pharma expected to maintain strong performance, providing access to 16,000 pharmacies in Europe and serving as a strategic connector for medical cannabis.

Market and Competitive Outlook:

• Cannabis Reform: U.S. federal reform anticipated to create significant long-term opportunities; Tilray positioned to act immediately if rescheduling occurs.
• Pricing Dynamics: Expecting price compression in international cannabis markets to persist, but offset by stronger product mix and operating efficiencies.
• U.S. Beer: Facing distributor consolidation and structural challenges; Tilray shifting from pure distributor dependence to direct retail engagement (Kroger, Walmart) to capture shelf space.
• Global Competition: Tilray views itself as a diversified global leader not dependent on a single regulatory catalyst, contrasting with pure-play U.S. cannabis operators.
• THC/Hemp Drinks: Anticipating a potential "carve-out" for hemp-derived THC in the upcoming U.S. farm bill extension; expecting Congress to approve specific milligram limits for sales.

Macro / Industry Outlook:

• Cost Headwinds: Monitoring fuel surcharges and inflationary input costs; however, cost leadership in Portugal (operating costs reduced ~40%) and Canada (lowering cost per gram) is mitigating these pressures.
• Regulatory Environment: Canada expected to grow by expanding product availability beyond dedicated cannabis stores (convenience stores, restaurants); EU markets driven by high standards and regulated patient access.
• Geopolitical Impact: Broader geopolitical landscape contributing to discrete cost headwinds (fuel surcharges), but underlying business performance remains strong.
• Tax/Excise: In Canada, Tilray pays >$100M CAD in excise tax; governments are looking to expand regulated cannabis sales to replace declining alcohol tax revenue.

Strategic Initiatives:

• M&A Strategy: Continuing to evaluate acquisitions and partnerships; focusing on brands that can be stabilized, integrated, and scaled globally. No specific M&A targets announced, but open to opportunities in India, Poland, France, Israel, and the Middle East for beverage expansion.
• Integration: BrewDog fully integrated with successful cost control and margin expansion; ongoing synergy realization between beverage and cannabis portfolios (shared overhead, infrastructure, and R&D).
• Capacity: Utilizing 6 million square feet of cultivation capacity globally; no need to acquire cultivation assets internationally due to existing low-cost supply chain (Portugal, Canada).
• Capital Allocation: Priorities include strengthening the balance sheet (reducing debt, currently $52M principal outstanding), reducing interest expense, and investing in high-return growth areas. No cash injections required for BrewDog since acquisition.
• Hospitality: Expanding BrewDog pubs/bars and existing Tilray hospitality venues (40+ globally) to enhance consumer touchpoints.

Risks and Headwinds to Outlook:

• U.S. Regulatory Delay: Continued delays in U.S. cannabis rescheduling impacting market sentiment and potential revenue realization.
• Price Compression: International cannabis markets facing continued price pressure, though margins are being defended through mix and cost reductions.
• Input Costs: Volatility in fuel surcharges and raw material costs (e.g., hemp seed shortages affecting wellness e-commerce).
• Geopolitical Events: Potential utility cost increases and supply chain disruptions due to global conflicts.
• Competition: Potential consolidation among international cannabis peers; domestic competitive pressure in the U.S. beer market.
• Implementation Risk: Execution of the U.S. beer turnaround strategy and full integration of global beverage platforms.

Management Tone on the Future:

• Confidence: Strong confidence in delivering FY2027 guidance despite short-term headwinds; emphasis on "multiple levers" to drive growth and margin expansion.
• Strategy Shift: Clear pivot from "growth at all costs" to "profitable growth," prioritizing margin expansion and cash generation over volume in saturated markets.
• Differentiation: Management emphasizes the company's diversified nature (cannabis, beverage, wellness, pharma) as a risk mitigation strategy against single-sector volatility.
• Long-term Vision: Optimistic about long-term structural growth in medical cannabis globally and the potential for THC beverage integration; views the business as "larger, more diversified, and more globally recognized."
• Tone: Disciplinary and proactive; acknowledges past losses but highlights immediate profitability in acquired assets (BrewDog) and cost control successes.

Miscellaneous:

• Balance Sheet Strength: Ended Q1 with $221 million in cash and marketable securities; settled >$42 million of debt year-to-date.
• Adjusted EBITDA: Q1 Adjusted EBITDA was $9.2 million, excluding a $1.7 million increase in fuel-related costs year-over-year.
• Profitability: Adjusted net loss of $3 million (excluding non-cash items), with $5 million attributed to net cash interest expense; adjusted net income would have been $2 million excluding interest.
• Share Count/Dividends: No specific announcements regarding share buybacks or dividends in this quarter; focus remains on debt reduction and organic reinvestment.